Evaluation of Image-Guided Liver Surgical System for Resection of Liver Cancer
NCT ID: NCT00782886
Last Updated: 2011-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
75 participants
OBSERVATIONAL
2008-04-30
2010-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Utility of Intra-operative Image Guidance System for Missing Metastases
NCT02806037
Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases
NCT01528878
Clinical Trial Comparing Carnoy's and GEWF Solutions
NCT02704988
Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
NCT07290764
I-FIGS Feasibility Study
NCT05616039
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient must be 18 years or older.
3. Patients recruited are male or non-pregnant, non-lactating females. Liver resection or ablation could be harmful to an unborn child, and therefore is not recommended during pregnancy. All consented patients of childbearing potential will be advised to use adequate birth control (oral, implanted, or barrier methods), along with their sexual partners, while being considered for liver tumor resection or ablation and one month following surgery.
4. Negative serum or urine pregnancy test result at screening in women of childbearing potential (applies to patients without documented menopause or sterility).
5. Patients enrolled must be candidates for surgical liver resection of liver cancer (primary or metastatic) or benign liver lesions (hemangioma, Focal Nodular Hyperplasia, Adenoma). Liver cancer must be present on preoperative imaging study (CT and/or MRI), if applicable.
6. Patient must be scheduled for surgical treatment of the liver cancer requiring the removal of at least one (1) anatomic segment.
\-
Exclusion Criteria
2. Patients that have a mental condition rendering them unable to understand informed consent to the nature, scope, and possible consequences of this study.
3. Patients requiring surgical intervention that extends beyond the liver, with the exception that extension into some adjacent structures might be allowed unless the liver is not the primary focus of the surgery AND the potential blood loss from the other surgical sites may jeopardize the safety of the patient. There is no absolute rule as to what adjacent structures would be allowed, thus prior approval must be obtained from the Medical Monitor listed above for all extrahepatobiliary surgery.
4. Patients with hereditary hematologic/coagulation disorders unrelated to their liver disease.
5. Patients with cirrhosis of the liver classified as Child's B or C. (See Appendix A)
6. Use of aspirin within 7 days prior to surgery or antiplatelet agents (i.e., Plavix) within 10 days prior to surgery or nonsteroidal anti-inflammatory medications within 48 hours prior to surgery.
7. Patients with thrombocytopenia (platelet counts below 100,000 per ml, White Count 3.0, Hemoglobin 10 or greater).
8. Patients who are currently (within the last 30 days prior to surgery) participating in another clinical trial with any investigational drug or device.
9. Patients undergoing liver surgery as a result of trauma.
10. Patients undergoing liver surgery for the purpose of receiving a liver transplant.
11. Patients undergoing liver surgery in which there is a single minor wedge resection on the surface of the liver.
12. Patients with established renal insufficiency (defined as creatinine greater than 2.5 mg/dl), or a condition that requires hemodialysis.
\-
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Pathfinder Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CRO
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Geller, M.D.
Role: PRINCIPAL_INVESTIGATOR
UPMC Liver Cancer Center
William Jarnagin, MD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Alan Hemming, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Florida Department of Surgery
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida Department of Surgery
Gainesville, Florida, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Pathfinder Therapeutics
Medelis Inc. (CRO)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PTI-LC-2007-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.